Lung Cancer

Article	Citations
Beyond environmental risk: Genetic insights into lung cancer susceptibility through whole exome analysis	106
123 Using Prescribing Data to Estimate the Number of ALKpositive Patients Currently Living in England	80
108 Evaluation of a Lung Cancer Nurse led clinic for the routine follow up of uncomplicated post resection lung cancer patients	71
190 Decision Making for Thoracic Radiotherapy and Prophylactic Cranial Irradiation in ES-SCLC Post Chemoimmunotherapy	66
Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer	63
175 External Validation of a Left Anterior Descending Coronary Artery Dose Constraint in Patients with Non-Small Cell Lung Cancer: An NI–HEART Analysis	63
251 Optimising engagement and addressing inequalities for patients using a Digital Behaviour Change Intervention in lung cancer prehabilitation: A mixed-methods study	61
190 Localised non-small cell lung cancer: patient characteristics and radical radiotherapy outcomes according to KRAS mutation status	61
260 Second Primary Lung Cancer Cohort Study (SPORT)	53
101 Treating advanced EGFR positive non-small cell lung cancer patients with Osimertinib - the University Hospital Plymouth experience	52
98 Hospitalisation Rates following Systemic Anti-Cancer Treatments for Patients with Non-Small Cell Lung Cancer	51
107 Osimertinib Efficacy in Advanced NSCLC Patients with PACC and Classical-Like EGFR Mutations: A Retrospective Analysis from The Christie	51
74 The first-in-class PRX3 inhibitor RSO-021 modulates the composition of malignant pleural effusions by eliciting immunomodulation and decreasing epithelial to mesenchymal protein expression	48
86 Real World Outcomes of Patients Receiving Neoadjuvant Treatment for Non-Small Cell Lung Cancer	46
89 Why do almost half of our patients not complete 12 months of maintenance durvalumab after successful radical chemoradiotherapy?	45
Contents	44
Title Page	44
Cell pellet from fixative medium of transbronchial lung biopsy sample improves lung cancer ancillary test	43
Putative mechanisms of primary resistance to EGFR-targeted therapies: A retrospective study	43
Retrospective review of patterns of recurrence in patients with a histological diagnosis of thymoma	42
Frailty, comorbidity and cardiovascular risk assessment in older patients with lung cancer	38
The first historical description of malignant mesotheliomas	37
The role of mediastinoscopy following EBUS	36
Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study	36
HALT: targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours	36

Antimuscarinics and lung cancer survival: A Norwegian population-based cohort study	35
Does consolidation radiotherapy to chest improve survival in extensive stage small cell lung cancer in the immunotherapy era? A retrospective study	35
Spatial microenvironment heterogeneity in therapy-naïve lung cancer: A concept with more attention needed	35
Direct to CT screening pilot for patients with COPD in a deprived area: longitudinal analysis of the pulmonary nodule cohort outcomes	35
Clinical relevance of circulating activin A and follistatin in small cell lung cancer	34
Exploration on the first-line treatment of ERBB2-altered advanced non-small cell lung cancer: A multicenter retrospective study	34
Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial	33
Clinical score for colorectal cancer patients with lung-limited metastases undergoing surgical resection: Meta-Lung Score	33
Author index	33
Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry	32
Real-world use of nivolumab plus ipilimumab in the management of diffuse pleural mesothelioma (DPM): experience from the county of Kent	32
Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis	32
Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers	31
Prediction of next generation sequencing test failure in lung adenocarcinoma in a genomic laboratory hub setting	31
Randomized controlled clinical trial is needed for toxicity of IMRT VS 3D-CRT in PORT for LA-NSCLC	31
Dynamic cytokines signature predicts survival outcome from severe Immune-related hepatitis with PD-1/PD-L1 blockade in lung cancer	30
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial	30
Immune landscape and novel therapeutic targets of epidermal growth factor receptor and anaplastic lymphoma kinase wild type never-smoker lung adenocarcinoma	29
Clinical implementation of value based healthcare: Impact on outcomes for lung cancer patients	29
Indwelling pleural catheter infections: a cautionary tale	29
A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival	29
Surgical or medical strategy for locally-advanced, stage IIIA/B-N2 non-small cell lung cancer: Reproducibility of decision-making at a multidisciplinary tumor board	28
Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer	28
Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers	28
WHO histological classification and tumor size are predictors of the locally aggressive behavior of thymic epithelial tumors	28
Evaluating lung cancer risk factors in adults with interstitial lung disease	27
Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the	27
Functional resilience and overall survival in adults treated for advanced non-small-cell lung cancer	27
Proposal of a revised International Association for the Study of Lung Cancer grading system in pulmonary non-mucinous adenocarcinoma: The importance of the lepidic proportion	26
HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer	26
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study	26
Advances in the treatment of brain metastases in EGFR-mutant non-small cell lung cancer	26
Frozen sections accurately predict the IASLC proposed grading system and prognosis in patients with invasive lung adenocarcinomas	25
Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer	25
Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinib	25
APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma	25
Two cases of non-small cell lung cancer patients with somatic or germline EGFR R776H mutation	25
Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial	25
143 Comparative Evaluation of Clinical Frailty Scale and WHO Performance Status For Predicting 90-day and One-year Mortality in People with Lung Cancer	24
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide	24
Imaging in pleural mesothelioma: A review of the 15th International Conference of the International Mesothelioma Interest Group	24
22 Challenges in Meeting Molecular Testing Turnaround Times in Lung Cancer	23
60 First-line Nivolumab/Ipilimumab in patients with unresectable malignant pleural Mesothelioma (MPM): West of Scotland experience	23
69 New research-based resources to facilitate engagement with palliative care for patients and families living with mesothelioma	23
67 The mental health and well-being implications of a mesothelioma diagnosis: a mixed methods study	23
37 Diagnostic performance across two high-volume EBUS services in Greater Manchester with and without Rapid On-Site Evaluation (ROSE)	23
135 The Impact of the Electronic Patient Record on Completion and Uploading of the Holistic Needs Assessment in Lung Cancer patients	23
31 The Nodules of Norfolk, Setting up a Pulmonary Nodule Pathway in a secondary care setting at the Norfolk & Norwich University Hospital – A reflective study over one year from January 2023 – Jan	23
95 Lorlatinib in advanced ALK-rearranged NSCLC – real-world experience in a UK population	22
219 “Fewer than 100 cigarettes in lifetime” deemed low risk for lung cancer – should we continue to offer Lung cancer screening to this cohort	22

Analyzing diagnostic and treatment wait times for lung cancer Patients: Key insights from a provincial registry study	22
206 Screening benefits and harms; a review of false positives and negatives from the Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Targeted Lung Health Check (TLHC) programme	22
Early pseudo-progression of brain metastases following tarlatamab therapy in relapsed small cell lung cancer	22
Prognostic impact of extracapsular extension of lymph nodes in resected lung cancer: analysis by new N subcategories and histologic types	22
204 REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm design	22
195 The impact of measured versus estimated height and weight on lung cancer screening eligibility – analysis from the Yorkshire Lung Screening Trial	22
Immune checkpoint inhibitors for advanced non-small cell lung cancer with preexisting COPD and CT-defined emphysema: A systematic review and meta-analysis	22
Contents	21
Initial experience of CT guided percutaneous microwave ablation of lung metastasis in a district general hospital	21
Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities	20
Contents	20
Contents	20
Predictive value and molecular correlates of MYC immunohistochemistry and copy number gain in non-small cell lung carcinomas treated with immunotherapy	20
Mutational analysis of pulmonary large cell neuroendocrine carcinoma: APC gene mutations identify a good prognostic factor	20
Clinicopathologic and genomic features of high-grade pattern and their subclasses in lung adenocarcinoma	20
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART	20
Lung cancer detection in the expanded Manchester Lung Health Check programme	20
Artificial intelligence-based recurrence prediction outperforms classical histopathological methods in pulmonary adenocarcinoma biopsies	20
Feasibility of salvage resection following locoregional failure after chemoradiotherapy and consolidation durvalumab for unresectable stage III non-small cell lung cancer	20
Contents	20
Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real–world	20
Two years on: progression free survival analysis of patients with advanced small cell lung cancer receiving atezolizumab plus etoposide and carboplatin in a tertiary oncology centre	19
Improving the use of NOACS for cancer-related VTE in Great Western Hospital	19
Assessing the impact of the pharmacist independent prescriber as part of the multi-disciplinary care of patients receiving adjuvant treatment for NSCLC	19
The impact of real-world lung cancer screening programmes on downstream diagnostic capacity	19
Rethinking continuity in primary care for people with mesothelioma	19
Impact and causes of readmission within 90-days of non-small cell lung cancer surgery	19
Contents	19
Impact of introducing intensity modulated radiotherapy (IMRT) on curative intent radiotherapy and survival for lung cancer	19
A District General Hospital (DGH) EBUS Service: a different model	18
Crucial, complex, caring: a new professional development framework for Lung Cancer Nurse Specialists	18
A combined model of circulating tumor DNA methylated SHOX2/SCT/HOXA7 and clinical features facilitates the discrimination of malignant from benign pulmonary nodules	18
Clinical application of the Lung Cancer Compact PanelTM using various types of cytological specimens in patients with lung cancer	18
11 Making an accurate diagnosis of anterior mediastinal lesions: A proposal for a new diagnostic algorithm from the BTOG Thymic Interest Group	18
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial	18
Real-world dosage, tolerability and clinical outcomes in patients with squamous NSCLC treated with carboplatin, paclitaxel and pembrolizumab in the West of Scotland	18
Effect of adherence to treatment guidelines on overall survival in elderly non-small-cell lung cancer patients	18
Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer	18
70 Trial protocol and update for the DREM study	17
173 Real world outcomes for patients receiving radical radiotherapy for stage 3 Non-Small Cell Lung Cancer post-PACIFIC	17
Construction and validation of a clinical differentiation model between peripheral lung cancer and solitary pulmonary tuberculosis	17
Commentary on: Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning	17
93 A regional-West Midlands audit on implementing the neo-adjuvant chemoimmunotherapy (NACIO) pathway for resectable non-small cell Cancer (NSCLC) patients	17
Spatiotemporal distribution of mediastinal neoplasms: A comprehensive multi-center study	17
193 The Impact of a Targeted Lung Health Check Program on Oncology Services at UHCW	17
Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)	17
56 High Frequency Jet Ventilation assisted CT guided lung biopsy service in a district general hospital	17
Prediction of prognosis in lung cancer using machine learning with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND)	17
Leptomeningeal metastases in non-small cell lung cancer: Diagnosis and treatment	17
109 Alk-positive NSCLC: Side effects - the real-world experiences of UK patients	16
Intrathecal nivolumab and IL-2 for treatment of leptomeningeal metastases in EGFR-mutated lung adenocarcinoma	16
Editorial Board	16
Corrigendum to “Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma – Interpretation guidance derived from two randomized EORTC trial	16
Contents	16
Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking	16
Predicting checkpoint inhibitors pneumonitis in non-small cell lung cancer using a dynamic online hypertension nomogram	16
Unradical Surgery for Locally-Advanced Thymoma: Is it time to evolve Perspectives?	16
198 Pilot lung screening in Scotland: intervention findings and qualitative insights	16
Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis	16
Perceived barriers to curative treatment for patients with early stage lung cancer: a mixed methods study	16
Evaluation of diagnostic algorithms for initial lung cancer investigation: are bundles safe and efficient?	16
Optimisation of the treatment pathway for stage III non-small cell cancer (NSCLC) patients receiving concurrent chemo-radiation (cCRT)	15
Understanding the mental health and well-being impacts and interventions related to living with mesothelioma: a systematic review	15
Research on the road: taking lung cancer research to the patient	15
Prognostic impact of adjuvant therapy for cisplatin-unfit patients with non-small-cell lung cancer: A multicenter analysis	15
A machine learning approach using clinical data for recurrence risk-stratification following radiotherapy for non-small cell lung cancer	15
A problem with clinical T factor in the 8th TNM edition: Prognosis and EGFR mutation status of small sized lung cancers with difficulty to measure the diameter of solid component in part-solid tumor	15
BLU-701 tumour suppression and intracranial activity as a single agent and in combination with BLU-945 in models of non-small cell lung cancer (NSCLC) driven by EGFR mutations	15
Endobronchial ultrasound–transbronchial nodal aspiration (EBUS-TBNA) with rapid on-site evaluation (ROSE) in the Ulster Hospital, 2021	15
Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendations	15
Drastic response of sunitinib after failure of Lenvatinib in patients with previously treated thymic carcinoma	15
ALK rearrangement is an independent predictive factor of unexpected nodal metastasis after surgery in early stage, clinical node negative lung adenocarcinoma	15
A case of lymphoepithelial carcinoma of the lung responding to treatment with pembrolizumab, paclitaxel and carboplatin	15
Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison	15
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study	14
Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation	14
157 Establishing a multidisciplinary habilitation clinic for lung cancer patients receiving radical radiotherapy	14
77 Toxicity and outcomes for patients with resected Non-Small cell lung cancer (NSCLC) who have received adjuvant chemotherapy in Bristol	14
Difference in efficacy of osimertinib between patients with EGFR-positive NSCLC with postoperative recurrence and those with de novo unresectable disease: A prospective, observational study	14
Immunogenicity of COVID-19 vaccines in lung cancer patients	14

Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study	14
Asbestos-Related lung Cancer: An underappreciated oncological issue	14
128 90 day admissions and mortality in lung cancer patients	14
46 Automated Derivation of Diagnostic Criteria for Lung Cancer using Natural Language Processing on Electronic Health Records: A pilot study	14
Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutations	14
Investigation on the survival implications of PD-L1 expression status in ALK- rearranged advanced non-small cell lung cancer treated with first-line crizotinib	14
Heavy mutagenesis by tobacco leads to lung adenocarcinoma tumors with KRAS G12 mutations other than G12D, leading KRAS G12D tumors—on average—to exhibit a lower mutation burden	14
Adherence to community-based lung cancer screening in the Yorkshire Lung Screening Trial	14
169 Can reminders improve lung cancer screening uptake amongst higher-risk populations?	14
54 A population-based review of early-onset lung cancer patients in Northern Ireland	14
Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition	14
Environmental asbestos exposure and lung cancer	13
174 The prevalence and clinical outcomes of incidental thymic lesions detected through Lung Cancer Screening	13
9 Evaluating outcomes in a district general hospital pleural service	13
Lung cancer caused by asbestos: What a reporting pathologist needs to know	13
114 The role of the Patient Cancer Care Coordinator in the Lung Cancer Pathway – reducing health inequalities and optimising patient access	13
Revisiting the lung cancer screening eligibility criteria to promote equity for Black individuals	13
Single-cell RNA-sequencing as a potential approach for studying intratumor heterogeneity in pleural mesothelioma	13
18 The impact of radiology reporting delays on lung cancer care: A single centre experience	13
109 Developing the role of the Lung Cancer Nurse Specialist (CNS) to support wider Clinical Practice beyond traditional role boundaries	13
51 Percutaneous tissue sampling in thoracic oncology - are core biopsies bigger and better?	13
Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMS	13
118 Occupational causes of respiratory cancers: Current and emerging trends and promoting prevention	13
Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer	13
33 Implementation of a Lung Oncology Virtual Ward (VW) – Accelerating Responsiveness to Personalised Care Management	13
86 Does entering clinical trials achieve better survival outcomes compared to standard of care in metastatic non-small cell lung cancer patients	13
EBUS audit: assessing the diagnostic performance of the service at UHL	12
182 Lung cancer findings from two Targeted Lung Health Check programmes running simultaneously across different geographically close regions and NHS trusts	12
254 Quality of life after radiotherapy treatment for patients with stage IV non-small cell Lung cancer: QUARTZ LUNG a Candidate-Specific Trial within the TOURIST Platform	12
132 A review of why patients with performance status 0-2 didn't receive anti-cancer treatment	12
Neoadjuvant immunotherapy in early-stage NSCLC: navigating biomarker dilemmas and special population challenges	12
Pulmonary blastoma is successfully treated with immunotherapy and targeted therapy	12
Corrigendum to “The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment” [Lung Cancer 165C (2022) 124–132]	12
Association between surgical quality and long-term survival in lung cancer	12
Current diagnostic and therapeutical approaches to bone metastases in patients with non-small cell lung cancer: A cross-sectional study	12
57 Real-world insights from the ctDNA transformation pilot funded by NHS England for patients with advanced non-small cell lung cancer (NSCLC) in South East England	12
ETV6::NTRK3 gene fusion in a patient with metastatic lung atypical carcinoid successfully treated with repotrectinib: A case report	12
PRIMALung (EORTC-1901-LCG): prophylactic cerebral irradiation or active brain magnetic resonance imaging surveillance in small-cell lung cancer patients	12
The issue of no tissue: lung cancer patients without a tissue diagnosis in NHS Lothian	12
Impact of perioperative fluids on clinical outcomes following thoracic surgery: a single-centre propensity matched retrospective study	12
TDP1 and TOP1 as targets in anticancer treatment of NSCLC: Activity and protein level in normal and tumor tissue from 150 NSCLC patients correlated to clinical data	12
257 SynthEtic LEthal Cancer Therapy in mesothelioma (SELECTmeso): a molecularly stratified multi-arm phase II platform trial for patients with relapsed malignant mesothelioma	12
227 CT Characteristics in Small Cell Lung Cancer: Prognostic Markers and Paraneoplastic Syndrome Associations	12
Type of lymphadenectomy does not influence survival in pIa NSCLC patients who underwent VATS lobectomy: Results from the national VATS group database	12
Long response to immune checkpoint inhibitors in metastatic NSCLC despite EGFR germline mutation. A case report	12
Improving community lung cancer follow-up strategies in South Greater Glasgow and Clyde using 1-year survival data	12
T cell immunity in interstitial lung disease with non-small cell lung cancer patients	11
Outcome of stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer (NSCLC)	11
Geographic variation in delay to surgical treatment among non-small cell lung cancer patients	11
Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non–small cell lung cancer	11
Hamlet.rt Trans: a prospective single-centre translational sub-study evaluation of liquid biomarkers of radiation response	11
PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC	11
Implementing adjuvant immunotherapy following radical chemoradiotherapy for stage III non-small cell lung cancer in UK clinical practice: are the PACIFIC trial outcomes achievable in the real world?	11
Contents	11
Event-free survival (EFS) with neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo by surgical outcomes in resectable non-small cell lung cancer (NSCLC) from CheckMate 81	11
A quality improvement study aiming to quantify anti-emetic steroid usage and documentation of consent and adverse effects in lung cancer patients	11
Occupational asbestos exposure and survival among lung cancer patients	11
Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Ca	11
Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression	11
Discovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma	11
Analyses of real-world data on patient outcomes in South Yorkshire, for patients with metastatic non-squamous lung cancer treated with pembrolizumab plus pemetrexed-platinum-based chemotherapy	11
Efficacy and surgical safety of sequential surgical resection after pembrolizumab plus chemotherapy for initial unresectable stage IIIB non-small cell lung cancer	11
Adjuvant immunotherapy after concurrent chemoradiation for locally advanced NSCLC: audit from Northern Ireland	11
Editorial Board	11
The genomic mutational landscape and its correlation with TMB, PD-L1 expression and CD8+ T cell infiltration in Chinese lung large cell neuroendocrine carcinoma	11
Contact with lung cancer patients during COVID-19: findings from Ireland and the UK from a global survey of patient experience	11
Lung cancer-associated T cell repertoire as potential biomarker for early detection of stage I lung cancer	11
237 Assessing the effectiveness of talc pleurodesis in the prevention of malignant pleural effusions at the Royal Gwent Hospital, Newport	11
CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer	11
SYSTEMS-2: a randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma	11
Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study	11
A comparison of patient- and clinician-assessed performance status and the role of wearable activity trackers to assist in performance status assessment in advanced cancer patients	11
Real world experience of hypofractionated radical radiotherapy for non-small cell lung cancer (NSCLC) during the COVID-19 pandemic: a well-tolerated radiotherapy schedule with acceptable progression-f	11
102 Real World Comparison between 1st line and 2nd line Osimertinib in Advanced/Metastatic EGFR mutated NSCLC at University Hospitals of Leicester.	10
187 Radiation pneumonitis following radical lung cancer radiotherapy: preliminary results from a logistic regression analysis	10
167 An evaluation of recruitment for research from a clinical Lung Cancer Screening service	10
172 Stage and Survival of Screen Detected Small Cell Lung Cancer from the SUMMIT Study	10
Moral distress in mesothelioma and lung cancer nurses during the COVID-19 pandemic: insights from a UK survey	10
How can lung Multi-Disciplinary Team Meetings (MDTMs) be transformed? An audit of MDTM caseloads and processes between MDTs across a cancer alliance	10
A novel cell-based assay for the high-throughput screening of epithelial–mesenchymal transition inhibitors: Identification of approved and investigational drugs that inhibit epithelial–mesenchymal tra	10
244 Recurrence pattern post surgical resection of lung cancer with curative intent	10
133 Prevalence of Latent Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A South-East London Cohort Study	10
10 Current challenges and delays in the lung cancer diagnostic pathway	10
Machine learning can predict lung cancer using primary care data	10
Is every PET positive lesion a lung cancer? Eight years outcome from a tertiary care hospital	10
Salford Targeted Lung Health Checks: a retrospective analysis of differences between responders and non-responders	10
Mesothelioma patient and carer experience: a study to identify research priorities	10
75 Improving Research Access for Mesothelioma Patients (IRAMP)	10
82 UK real world study of patients who do not proceed to surgery following neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer (NSCLC)	10
45 Optimisation of an EBUS service at a district general hospital	10
A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer	10
Outcomes of open access to CT scanning in suspected lung malignancy in patients in Lincolnshire	10
Process mining as a research tool to evaluate care pathways for patients with an indeterminate pulmonary nodule demonstrates the high variability between patient pathways across a region	10
Gross tumour volume predicts survival and correlates with pre-treatment serum albumin concentration in patients with stage III non-small cell lung cancer treated with chemo-radiotherapy	10
203 Setting up a county-wide targeted lung health check (TLHC) programme in Dorset, run through a district general hospital (DGH)	10